On March 12, 2026, Clene Inc. announced its full year operating and financial results for 2025, highlighting an oversubscribed direct offering of over $28 million and a cash runway extending into 2027. The company expects to file an NDA for its ALS treatment by mid-2026.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.